ANTONI RIBAS

Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology LOS ANGELES, CA NPI 1730109331

General Payments — all program years on this page

$368,584.92

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 133
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $36,598.51 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $26,007.007
Travel and Lodging $9,824.426
Food and Beverage $767.096

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
F. Hoffmann-La Roche AG $21,947.787
Amgen Inc. $8,988.115
Merck Sharp & Dohme Corporation $4,001.044
Almirall LLC $1,650.001
ARRAY BIOPHARMA INC $11.582

By program year

Program yearAmountRecords
2018 $56,616.5047
2019 $58,382.6639
2020 $29,495.2515
2021 $6,400.003
2022 $179,357.008
2023 $1,735.002
2024 $36,598.5119

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1117665805 Amgen Inc. $8,232.00 09/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1117665807 Amgen Inc. $212.05 08/08/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1117665809 Amgen Inc. $242.54 08/08/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1117665811 Amgen Inc. $58.98 08/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117665813 Amgen Inc. $242.54 08/09/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1120643723 Almirall LLC $1,650.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1131367757 ARRAY BIOPHARMA INC $2.88 09/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131473362 ARRAY BIOPHARMA INC $8.70 12/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1132978035 F. Hoffmann-La Roche AG $422.32 03/05/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1132978037 F. Hoffmann-La Roche AG $8,553.86 03/05/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1132978039 F. Hoffmann-La Roche AG $81.83 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1132978041 F. Hoffmann-La Roche AG $578.66 03/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1132978043 F. Hoffmann-La Roche AG $8,360.00 03/05/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1132978045 F. Hoffmann-La Roche AG $151.11 03/05/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1132978047 F. Hoffmann-La Roche AG $3,800.00 03/06/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141756518 Merck Sharp & Dohme LLC $1,220.00 10/02/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141817457 Merck Sharp & Dohme LLC $36.04 09/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141817459 Merck Sharp & Dohme LLC $2,135.00 11/18/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141888443 Merck Sharp & Dohme LLC $610.00 08/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.